Do Physicians Find Our AST Reports As Confusing As We Do? Louis B. Rice, M.D. Louis Stokes Cleveland VA Medical Center and Case Western Reserve University.

Slides:



Advertisements
Similar presentations
Direct Sensitivity Performed when : * Gram stain shows large number of one type of reaction * To get quick result for serious cases * Used only.
Advertisements

TREATMENT FOR SUPERIMPOSED PSEUDOMONAS AERUGINOSA INFECTION.
BETHLEHEM UNIVERSITY Second Neonatal Gathering Fall 2007.
Subtle Imipenem Resistance In an ICU Outbreak of Acinetobacter-baumanii calcoaceticus (ACBC) Sandy J. Close, Pharm.D., BCPS, Steven J. Martin, Pharm.D.,
Lecture 3 Antimicrobials and Susceptibility tests Dr. Abdelraouf A. Elmanama Islamic University-Gaza Medical Technology Department.
Plasmids Chromosome Plasmid Plasmid + Transposon Plasmid + integron Plasmid+transposon +intergron Chromosome Chromosome + transposon Chromosome + transposon.
Should we change the recommendations related to antibiotic drug dosage/drug duration? Workshop on Economic Epidemiology Makerere University August, 2009.
Pharmacodynamics of Antibiotics
Office of Clinical Pharmacology and Biopharmaceutics IDSA/ISAP/FDA Workshop 4/16/04 1 Improvement in Dose Selection: FDA Perspective IDSA/ISAP/FDA Workshop.
MDR Organisms in Holy Family Hospital Rawalpindi
BSAC User Group Meeting 2007 BSAC recommendations for interpreting the susceptibility of urinary tract isolates Jenny Andrews.
Antibiotics Tamar Barlam Infectious Disease Director, Antimicrobial Stewardship.
Frequency of Antibiotic Resistance among Bacteria Isolated From a High School Setting Katie Amato Columbia High School.
PK/PD of Antibiotics in relation to resistance Otto Cars MD Department of Medical Sciences Infectious diseases Uppsala University Sweden.
In Vitro Testing of Antimicrobial Agents Maryam Monajemzadeh, Pathologist Children Medical Center Hospital Tehran University Of Medical Sciences.
Understanding the Clinical Microbiology Laboratory Carol R. Quinter Ph.D. January, 2007.
Aims of study This surveillance study was performed to determine the in vitro activity of ciprofloxacin against clinical isolates of Escherichia coli and.
AMINOGLYCOSIDES The different members of this group share many properties in common. The different members of this group share many properties in common.
Zunilda Djanun*, Rudyanto S**, Yulia Rosa***, *Dept. Clinical Pharmacology FMUI/CMH, **ICU CMH, *** Dept. Clinical Microbiology FMUI.
Antimicrobial Resistance patterns among nosocomial gram negative bacilli by E-test and disc diffusion methods in Sina and Imam Hospital.
Interpretation/Evaluation of Laboratory Data CLS 552 Human Microbiology & Immunology Laboratory Note: View this PowerPoint as a ‘Full Screen Slide Show’.
Center for Drug Evaluation and Research March 6, 2005 Bacteremia and Endocarditis: Products and Guidance Janice Soreth, MD Director Division of Anti-Infective.
Evaluating the Safety of Antimicrobial New Animal Drugs with Regard to Their Microbiological Effects on Bacteria of Human Health Concern Qualitative Antimicrobial.
Guideline for the Diagnosis and Management of Adults in LTC with Urinary Tract Infection (Part 2) This is intended as a guide for evidence-based decision-making.
The Efficacy of Topical Manuka Honey and Combination Antibiotic Therapy in the Treatment of MRSA Skin Infections Kyle Liban Pacific University School of.
Phage therapy for the treatment for urinary tract infection: Results of in-vitro screenings and in-vivo application using commercially available bacteriophage.
Multi-Resistant Gram Negative Microorganisms St Elisabeth Hospital Curacao.
Using Nursing Home Antibiograms To Improve Antibiotic Prescribing and Delivery Training Slides for Nursing Home Nurses Comprehensive Antibiogram Toolkit.
Adequacy of beta-lactam antibiotic dosing in critically ill children on continuous renal replacement therapy: A pilot study. Diaz F 1,2, Benner KW 3, Sewell.
Lab: 6 ANTIBIOTIC SENSITIVITY TESTING
"Don't forget to take a handful of our complimentary antibiotics on your way out“
PRINCIPLES OF ANTIBIOTIC THERAPY
Tapasyapreeti Mukhopadhyay, Vrushali Patwardhan, Sarman Singh
Kiran Ghimire, Baral B., Karna S., Baral M.P. PhD
Table 3 Clinical response success rate, according to prior effective antimicrobial therapy in hospitalized patients with community-acquired pneumonia given.
Antimicrobial Susceptibility Testing (AST)
International Journal of Infectious Diseases
The Role of the Microbiology Laboratory in AMS programs
Volume 115, Issue 3, Pages 19S-23S (March 1999)
Antibiotics sensitivity of microorganism causing nosocomial infections
Antimicrobial susceptibility testing of colistin – evaluation of seven commercial MIC products against standard broth microdilution for Escherichia coli,
Development of resistance in Pseudomonas aeruginosa obtained from patients with cystic fibrosis at different times  F.B. Spencker, L. Staber, T. Lietz,
AST SC’s Perspective on the Development and Use of ECVs
Simone M. Shurland, Ph.D., Division of Anti-Infective Products
Introduction: Results: Methodology: Discussion: Conclusion:
Hospital Antibiotic Stewardship Programs
Antibiogram By:Dr. S. S. Khoramrooz In the name of God
MIC Where does that number come from?
Pharmacokinetics and pharmacodynamics of fluoroquinolones
Antimicrobial susceptibility results for a multi-drug resistant Pseudomonas isolated from a case of otitis externa in a dog. Antimicrobial susceptibility.
Redefining susceptibility testing categories S, I and R.
C th Interscience Conference on Antimicrobial Agents and Chemotherapy October 25-28, Washington, DC Examining Temocillin Activity in Combination.
Meropenem in cystic fibrosis patients infected with resistant Pseudomonas aeruginosa or Burkholderia cepacia and with hypersensitivity to β-lactam antibiotics 
Cell-wall-inhibiting antibiotic combinations with activity against multidrug-resistant Klebsiella pneumoniae and Escherichia coli  R.A. Hickman, D. Hughes,
C.G. Giske, C. Borén, B. Wretlind, G. Kronvall 
ANTIBIOTIC RESISTANCE
A multicentre analysis of epidemiology of the nosocomial bloodstream infections in Japanese university hospitals  M. Nagao  Clinical Microbiology and.
P. Moreillon, J.M. Entenza  Clinical Microbiology and Infection 
…monitoring trends in antimicrobial resistance in Canada
Multicenter study of the in vitro activity of cefepime in comparison with five other broad- spectrum antibiotics against clinical isolates of Gram-positive.
In vitro selective concentrations of cefepime and ceftazidime for AmpC β-lactamase hyperproducer Enterobacter cloacae variants  Maria-Cristina Negri,
A comparative study of the in vitro activity of meropenem and representatives of the major classes of broad-spectrum antibiotics  J. Moira Greenhalgh,
M.R. Jacobs  Clinical Microbiology and Infection 
Comparative antimicrobial spectrum and activity of the desfluoroquinolone BMS (T-3811) tested against non-fermentative Gram-negative bacilli  W.
Volume 151, Issue 4, Pages (April 2017)
…monitoring trends in antimicrobial resistance in Canada
Susceptibility of multi-drug-resistant Pseudomonas aeruginosa in intensive care units: results from the European MYSTIC study group†   H. Goossens  Clinical.
…monitoring trends in antimicrobial resistance in Canada
…monitoring trends in antimicrobial resistance in Canada
J. Segreti  Clinical Microbiology and Infection 
Presentation transcript:

Do Physicians Find Our AST Reports As Confusing As We Do? Louis B. Rice, M.D. Louis Stokes Cleveland VA Medical Center and Case Western Reserve University Cleveland, Ohio

Purpose of Study To determine whether the results generated by Microbiology laboratory are easily interpretable by medical staffTo determine whether the results generated by Microbiology laboratory are easily interpretable by medical staff To determine whether microbiologic concepts inherent in some of our reports (and assumptions) are understood by practicing cliniciansTo determine whether microbiologic concepts inherent in some of our reports (and assumptions) are understood by practicing clinicians

Methods Fourteen item questionnaire administered to physicians at various levels in two Cleveland hospitalsFourteen item questionnaire administered to physicians at various levels in two Cleveland hospitals Personal information requested, but not requiredPersonal information requested, but not required Individual results available on requestIndividual results available on request

Disclaimers This is not a scientifically validated studyThis is not a scientifically validated study This is not a random sample of Medical StaffThis is not a random sample of Medical Staff

Acknowledgement This survey was developed, administered and analyzed with the indispensable and highly professional assistance of Klara Papp, Ph.D.This survey was developed, administered and analyzed with the indispensable and highly professional assistance of Klara Papp, Ph.D.

Question #1 A Minimal Inhibitory Concentration (MIC) is defined as: A. The minimal concentration of an antibiotic required to kill the test organism B. The minimal concentration of an antibiotic required to prevent growth of a standard inoculum of test organisms C. The minimal concentration of an antibiotic achievable in human serum D. The minimal concentration of an antibiotic achievable in human urine 90% 9% 1%

Question #2 What is a breakpoint? A. The concentration of an antibiotic required to inhibit growth of an organism in vitro B. The concentration of an antibiotic that becomes toxic to human tissues C. The MIC determined to represent a high likelihood for successful treatment of a bacterial strain with a specific antibiotic 5% 25% 68%

Question #3 Who defines the breakpoints for different antibiotics? A. The American Society for Microbiology B. The Food and Drug Administration C. The National Committee for Clinical Laboratory Standards D. The American College of Physicians 16% 37% 45% 1%

Question #4 Important considerations in determining breakpoints for specific antibiotics include: A. Achievable serum concentrations of the antibiotic B. The pharmacokinetics of the antibiotic C. The pharmacodynamics of antibiotic-organism interactions in animal studies D. All of the above 14% 1% 84%

Question #5 Is the Klebsiella oxytoca susceptible to meropenem? A. Yes B. No

Bacteriology Final Report – K. oxytoca AntibioticSusceptibilityInterpretation Amikacin <= 2 S Ampicillin >= 32 R Cefazolin R Ceftazidime>=32R Trimethoprim-sulfa>=320R Meropenem <= 2 S Gentamicin >= 16 R Ampicillin/sulbactam >= 32 R Levofloxacin4I CefotetanII Cefepime <= 4 S Piperacillin/tazobactam64I

Question #5 Is the Klebsiella oxytoca susceptible to meropenem? A. Yes B. No 95% 3%

Question #7 What is the breakpoint for Pseudomonas aeruginosa resistance to ceftazidime? A. >=8 B. >=32 C. Insufficient information

Bacteriology Final Report – P. aeruginosa AntibioticSusceptibilityInterpretation AmikacinSS Ampicillin Cefazolin CeftazidimeSS Trimethoprim-sulfaRR MeropenemRR GentamicinRR Ampicillin/sulbactam LevofloxacinRR Cefotetan CefepimeSS Piperacillin/tazobactamSS

Question #7 What is the breakpoint for Pseudomonas aeruginosa resistance to ceftazidime? A. >=8 B. >=32 C. Insufficient information 7% 14% 77%

Question #8 Under what circumstances would the results of the enterococcal synergy testing shown in this report be useful? A. For the treatment of urinary tract infection B. For the treatment of infections in which Gram negative bacilli are also involved C. For the treatment of endocarditis D. Synergy testing is never useful 20% 8% 64% 6%

Question #9 The K. oxytoca is of intermediate susceptibility to both levofloxacin and piperacillin-tazobactam. However, the MIC for levofloxacin is 4 and piperacillin-tazobactam 64. Does this mean that levofloxacin will be a more effective therapeutic agent in this case? A. Yes B. No 22% 74%

Answers to Why Most commented appropriately on achievable serum levels, etc.Most commented appropriately on achievable serum levels, etc. “It takes more dilutions of pip-tazo to lose its effectiveness than levofloxacin”“It takes more dilutions of pip-tazo to lose its effectiveness than levofloxacin” “MIC determines dose, not susceptibility”“MIC determines dose, not susceptibility” “Other factors are relevant such as…likelihood of developing further resistance”“Other factors are relevant such as…likelihood of developing further resistance”

Question #10 In what type of infection could you use levofloxacin with greatest confidence against this strain of K. oxytoca? A. Abdominal abscess B. Aspiration pneumonia C. Urinary tract infection D. Osteomyelitis 9% 9% 2% 75% 7%

Answers to Why Most commented appropriately on achievable urine levelsMost commented appropriately on achievable urine levels

Question #12 Is the Pantoea strain described above susceptible to cefotetan? A. Yes B. No

Bacteriology Final Report - Pantoea AntibioticSusceptibilityInterpretation Ampicillin >= 32 R Cefazolin R Ceftazidime>=32R Trimethoprim-sulfa<=10S Meropenem <= 2 S Gentamicin <= 0.05 S Ampicillin/sulbactam >= 32 R Levofloxacin <= 1 S Cefotetan32I Cefepime <= 4 S Piperacillin/tazobactam32I

Question #12 Is the Pantoea strain described above susceptible to cefotetan? A. Yes B. No 44% 52% 52%

Bacteriology Final Reports – E. cloacae Antibiotic First Culture Second Culture Ampicillin >= 32, R Cefazolin Ceftazidime <=8, S >= 32, R Trimethoprim-sulfa <=10, S Meropenem <= 2, S Gentamicin <= 0.5, S Ampicillin/sulbactam >= 32, R Levofloxacin <= 1, S Cefotetan >= 64, R Cefepime <= 4, S Piperacillin/tazobactam 32, I >= 128, R

Question #13 The above culture was taken one week after the culture shown earlier. Is it likely that the Enterobacter isolates represent the same strain from two different cultures? A. Yes, because both are susceptible to cefepime. B. No, because their susceptibilities to piperacillin-tazobactam and ceftazidime differ. C. They could be the same or different. You cannot tell without performing more detailed genetic studies. 16% 9% 70%

Question #14 What is the breakpoint for cefotetan resistance for the Enterobacter cloacae? A. 32 B. 64 C. 128

Breakpoint for Cefotetan Enterobacter cloacae Pantoeae SuscIntpSuscIntp Cefotetan >= 64 R32I

Question #14 What is the breakpoint for cefotetan resistance for the Enterobacter cloacae? A. 32 B. 64 C % 18% 13%

Random Comments I know I need to review this – how embarrassing!I know I need to review this – how embarrassing! Note to Dr. Rice: You’re right! We do learn too much cardiology and not enough ID in our programNote to Dr. Rice: You’re right! We do learn too much cardiology and not enough ID in our program

Conclusions Clinicians are more adept at interpreting Microbiology laboratory reports than we give them credit forClinicians are more adept at interpreting Microbiology laboratory reports than we give them credit for The subtleties of antimicrobial testing are understood by most medical staff under the conditions of this testThe subtleties of antimicrobial testing are understood by most medical staff under the conditions of this test However, this understanding is not complete, and will benefit from expert Infectious Diseases input in complicated casesHowever, this understanding is not complete, and will benefit from expert Infectious Diseases input in complicated cases